Noradrenergic activity differentially regulates the expression of rolipram-sensitive, high-affinity cyclic AMP phosphodiesterase (PDE4) in rat brain

Journal of Neurochemistry

Volumn 69, Issue 6, 1997, Pages 2397-2404

  Ye, Ying ^a,d   Conti, Marco ^b   Houslay, Miles D ^c   Farooqui, Shakeel M ^a   Chen, Ming ^a   O'Donnell, James M ^a  

^a LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d Louisiana State University Health Sciences Center at Shreveport   (United States)

Author keywords

6 Hydroxydopamine; Desipramine; Immunoblot analysis; Noradrenergic system; Phosphodiesterase; Propranolol

Indexed keywords

CYCLIC AMP; PHOSPHODIESTERASE; PROPRANOLOL DERIVATIVE; ROLIPRAM;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; DOSE RESPONSE; DOWN REGULATION; ENZYME ASSAY; HOMEOSTASIS; IMMUNOBLOTTING; NEUROTRANSMISSION; NONHUMAN; NORADRENERGIC SYSTEM; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; RAT; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 0030657498     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1997.69062397.x     Document Type: Article

References (37)

1. Alvarez R., Sette C., Yang D., Eglen R. M., Wilhelm R., Shelton E. R., and Conti M. (1995) Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3. Mol. Pharmacol. 48, 616-622.
2. Beavo J. A., Conti M., and Heaslip R. J. (1994) Multiple cyclic nucleotide phosphodiesterases. Mol. Pharmacol. 46, 399-405.
3. Bobon D., Breulet M., Gerard-Vandenhove M. A., Guiot-Goffioul F., Plonteux G., Sastre-y-Hernandez M., Schratzer M., Troisfontaines B., Vov-Frenckell R., and Wachtel H. (1988) Is phosphodiesterase inhibition a new mechanism of antidepressant action? A double blind double-dummy study between rolipram and desipramine in hospitalized major and/or endogenous depressives. Eur. Arch. Psychiatry Neurol. Sci. 238, 2-6.
4. Bolger G. B. (1994) Molecular biology of the cyclic AMP-specific cyclic nucleotide phosphodiesterases: a diverse family of regulatory enzymes. Cell. Signal. 6, 851-859.
5. Bolger G. B., Rodgers L., and Riggs M. (1994) Differential CNS expression of alternative mRNA isoforms of the mammalian genes encoding cAMP-specific phosphodiesterases. Gene 149, 237-244.
6. Bolger G. B., McPhee I., and Houslay M. D. (1996) Alternative splicing of cAMP-specific phosphodiesterase mRNA transcripts. J. Biol. Chem. 271, 1065-1071.
7. Bradford M. M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254.
8. Challiss R. A. and Nicholson C. D. (1990) Effects of selective phosphodiesterase inhibition on cyclic AMP hydrolysis in rat cerebral cortical slices. Br. J. Pharmacol. 99, 47-52.
9. Conti M., Nemoz G., Sette C., and Vicini E. (1995) Recent progress in understanding the hormonal regulation of phosphodiesterases. Endocr. Rev. 16, 370-389.
10. Eison L. S., Yocca F. D., and Gianutsos G. (1988) Noradrenergic denervation alters serotonin2-mediated behavior but not serotonin2 receptor number in rats: modulatory role of beta adrenergic receptors. J. Pharmacol. Exp. Ther. 246, 571-577.
11. Engels P., Fichtel K., and Lubbert H. (1994) Expression and regulation of human and rat phosphodiesterase type IV isogenes. FEBS Lett. 350, 291-295.
12. Fleischhacker W. W., Hinterhuber H., Bauer H., Pflug B., Berner P., Simhandl C., Wolf R., Gerlach W., Jaklitsch H., Sastre-y-Hernandez M., Schmeding-Wiegel H., Sperner-Unterweger B., Voet B., and Schubert H. (1992) A multicenter double-blind study of three different doses of the new cAMP-phosphodiesterase inhibitor rolipram in patients with major depressive disorder. Neuropsychobiology 26, 59-64.
13. Griebel G., Misslin R., Vogel E., and Bourguignon J. (1991) Behavioral effects of rolipram and structurally related compounds in mice: behavioral sedation of cAMP phosphodiesterase inhibitors. Pharmacol. Biochem. Behav. 39, 321-323.
14. Griswold D. E., Webb E. F., Breton J., White J. R., Marshall P. J., and Torphy T. J. (1993) Effect of selective phosphodiesterase type IV inhibitor, rolipram, on fluid and cellular phases of inflammatory response. Inflammation 17, 333-344.
15. m, rolipram-sensitive cAMP phosphodiesterase mapping of the catalytic domain. J. Biol. Chem. 267, 18929-18939.
16. B2) in brain: selective localization in membrane and cytosolic compartments and differential expression in various brain regions. Biochem. J. 304, 399-406.
17. McPhee I., Pooley L., Lobban M., Bolger G., and Houslay M. D. (1995) Identification, characterization and regional distribution in brain of RPDE-6 (RNPDE4A5), a novel splice variant of the PDE4A cyclic AMP phosphodiesterase family. Biochem. J. 310, 965-974.
18. Naro F., Zhang R., and Conti M. (1996) Developmental regulation of unique adenosine 3′,5′-monophosphate-specific phosphodiesterase variants during rat spermatogenesis. Endocrinology 137, 2464-2472.
19. O'Donnell J. M. (1990) Behavioral effects of beta adrenergic agonists and antidepressant drugs after down-regulation of beta-2 adrenergic receptors by clenbuterol. J. Pharmacol. Exp. Ther. 254, 147-154.
20. O'Donnell J. M. (1993) Antidepressant-like effects of rolipram and other inhibitors of cyclic AMP phosphodiesterase on behavior maintained by differential reinforcement of low response rate. J. Pharmacol. Exp. Ther. 264, 1168-1178.
21. O'Donnell J. M. and Frazer A. (1985) Effects of clenbuterol and antidepressant drugs on beta adrenergic receptor/N-protein coupling in the cerebral cortex of the rat. J. Pharmacol. Exp. Ther. 234, 30-36.
22. O'Donnell J. M. and Seiden L. S. (1983) Altered effects of desipramine on operant performance after 6-hydroxydopamine-induced depletion of brain dopamine or norepinephrine. J. Pharmacol. Exp. Ther. 229, 629-635.
23. Sette C., Iona S., and Conti M. (1994a) The short-term activation of a rolipram-sensitive, cAMP specific phosphodiesterase by TSH in thyroid FRTL-5 cells is mediated by a cAMP-dependent phosphorylation. J. Biol. Chem. 269, 9245-9252.
24. Sette C., Vicini E., and Conti M. (1994b) The ratPDE3/IVd phosphodiesterase gene codes for multiple proteins differentially activated by cAMP-dependent protein kinase. J. Biol. Chem. 269, 18271-18274.
25. Shakur Y., Wilson M., Pooley L., Lobban M., Griffiths S. L., Campbell A. M., Beattie J., Daly C., and Houslay M. D. (1995) Identification and characterization of the type-IVA cyclic AMP-specific phosphodiesterase RD1 as a membrane-bound protein expressed in cerebellum. Biochem. J. 306, 801-809.
26. Siegel S. (1956) The case of two independent samples, in Nonparametric Statistics for the Behavioral Sciences (Morgan C. T., ed), pp. 95-158. McGraw-Hill, New York.
27. Smith P. K., Krohn R. I., Hermanson G. T., Mallia A. K., and Gartner F. H. (1985) Measurement of protein using bicinchoninic acid. Anal. Biochem. 150, 76-85.
28. Swinnen J. V., Joseph D. R., and Conti M. (1989a) The mRNA encoding a high-affinity cAMP phosphodiesterase is regulated by hormones and cAMP. Proc. Natl. Acad. Sci. USA 86, 8197-8201.
29. Swinnen J. V., Joseph D. R., and Conti M. (1989b) Molecular cloning of rat homologues of the Drosophila melanogaster dunce cAMP phosphodiesterase: evidence for a family of genes. Proc. Natl. Acad. Sci. USA 86, 5325-5329.
30. Swinnen J. V., Tsikalas K. E., and Conti M. (1991) Properties and hormonal regulation of two structurally related cAMP phosphodiesterases from the rat Sertoli cell. J. Biol. Chem. 266, 18370-18377.
31. Torphy T. J., Zhou H. L., and Cieslinski L. B. (1992) Stimulation of beta adrenoceptors in a human monocyte cell line (U937) up-regulates cyclic AMP-specific phosphodiesterase activity. J. Pharmacol. Exp. Ther. 263, 1195-1205.
32. Torphy T. J., Zhou H. L., Foley J. J., Sarau H. M., Manning C. D., and Barnette M. S. (1995) Salbutamol upregulates PDE4 activity and induces a heterologous desensitization of U937 cells to prostaglandin E2. J. Biol. Chem. 270, 23598-23604.
33. Verghese M. W., McConnell R. T., Lenhard J. M., Harnacher L., and Jin S.-L. C. (1995) Regulation of distinct cyclic AMP-specific phosphodiesterase (phosphodiesterase type 4) isozymes in human monocytic cells. Mol. Pharmacol. 47, 1164-1171.
34. Wachtel H. and Schneider H. H. (1986) Rolipram, a novel antide-pressant drug, reverses the hypothermia and hypokinesia of monoamine-depleted mice by an action beyond postsynaptic monoamine receptors. Neuropharmacology 25, 1119-1126.
35. Whalin M. E., Garrett R. L., Thompson W. J., and Strada S. J. (1989) Correlation of cell-free brain cyclic nucleotide phosphodiesterase activities to cyclic AMP decay in intact brain slices. Second Messengers Phosphoproteins 12, 311-325.
36. Winer B. J. (1971) Inference with respect to means and variance, in Statistical Principles in Experimental Design (Maytham W., Shapiro A., and Stern J., eds), pp. 4-54. McGraw-Hill, New York.
37. Ye Y. and O'Donnell J. M. (1996) Diminished noradrenergic stimulation reduces the activity of rolipram-sensitive, high-affinity cyclic AMP phosphodiesterase in rat cerebral cortex. J. Neurochem. 66, 1894-1902.